Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 6,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: GastroEsophageal Cancer
Interventions: Immune checkpoint inhibitor (ICI) or chemotherapy alone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Cell Carcinoma, Ovarian Tumor
Interventions: DS-6000a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Lake Mary, Florida + 2 more

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 26
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer
Interventions: AMG 228; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: La Jolla, California • New Haven, Connecticut • New York, New York

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions: CTX-471, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Sacroiliitis, Sacroiliac Joint Pain
Interventions: sacroiliac joint injection; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Childhood Cancer
Interventions: Mila Blooms; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 19 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Total Hip Arthroplasty
Interventions: Real-time Instrumentation, Standard Total Hip Arthroplasty; Device · Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer, Cardiovascular Disease
Interventions: Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor; Behavioral · Drug
Lead sponsor: McMaster University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 4
States / cities: Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more

Conditions: Pain
Interventions: Slow, Room Temperature Injection, Rapid, Room Temperature Injection, Slow, Warm Temperature Injection, Rapid, Warm Temperature Injection, Buffered Injection, Non-Buffered Injection, Lidocaine, Buffer; Procedure · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hematologic Malignancies
Interventions: StemEx; Biological
Lead sponsor: Loyola University; Other
Eligibility: 55 Years to 73 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Healthy Volunteers Food Interaction Study
Interventions: AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Odronextamab multiple dose levels; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Tampa, Florida + 4 more

Conditions: Caries
Interventions: Calcium sodium phosphosilicate, Sodium monoflurophosphate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Colorectal Cancer
Interventions: Panitumumab, Cabozantinib; Biological · Drug
Lead sponsor: John Strickler, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Personal Satisfaction
Interventions: Hyaluronic acid filler injection; Procedure
Lead sponsor: Marmur Medical; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Concussion, Brain
Interventions: Not listed
Lead sponsor: ElMindA Ltd; Industry
Eligibility: 12 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brighton, Michigan

Conditions: HIV
Interventions: Monetary Incentive, Questionnaire Timing, HIV Test Offering; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 64 Years
Enrollment: 8,572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Small-Cell Lung
Interventions: Canakinumab, Docetaxel, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more

Conditions: Metastatic Colorectal Cancer
Interventions: Futuximab/modotuximab, Trifluridine/Tipiracil; Biological · Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 15 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Bipolar Disorder
Interventions: CARE, Treatment As Usual; Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Cranston, Rhode Island • Providence, Rhode Island

Conditions: Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Day to 2 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more

Search by objective public record fields.

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Safety Study of AMG 228 to Treat Solid Tumors

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Imaging for SIJ Injection Therapy

Mila Blooms Intervention Study

Real-Time Instrument for Acetabular Shell Positioning

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Pain Perception: Lidocaine Rate/Temp/Buffer

Umbilical Cord Transplantation for the Elderly Population

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Hyaluronic Acid Filler for Dorsal Finger Volume Loss

Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment, Young Adults and Adults

HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)

DCE MRI in Patients With Pancreatic Cancer

Project CARE: An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Pilot RCT

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)